Wim Goettsch, PhD is currently Special Advisor HTA at the Dutch National Health Care Institute He was the Director of the EUnetHTA JA3 (2016-2021) Directorate and Chair of the Executive Board of EUnetHTA between June 2016 and March 2018. Since December 1, 2022, he has a part-time position as a Professor of HTA of Pharmaceuticals at Utrecht University (NL) where he is leading a new H2020 consortium with fifteen partners around Europe, called HTx, new methods for Health Technology Assessment (2019-2024). Between 2010 and 2013, he was the Deputy Secretary of the Medicinal Products Reimbursement Committee at Dutch National Health Care Institute. He is currently Director in the Board of HTAi (2019-2022) and involved many activities on real-world evidence (RWE) such as the IMI-GetReal Institute, the ISPOR RWE Transparency Steering Committee, the ISPE-ISPOR taskforce on RWE transparency, CIOMS WG XII on RWE and the INAHTA position workgroup on RWE. Before joining the National Health Care Institute, he worked as a research manager for the PHARMO Institute and was responsible for the coordination of numerous pharmacoepidemiological and outcomes studies for international offices of pharmaceutical companies such as AstraZeneca, Novartis, Pfizer and GSK. He has a PhD in immunology and an advanced education in (pharmaco)- epidemiology and pharmaco-economics. He has more than 120 publications in peer-reviewed international journals.